{"id":"ramipril-irbesartan","safety":{"commonSideEffects":[{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Cough"},{"rate":null,"effect":"Hyperkalemia"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL1168","moleculeType":"Small molecule","molecularWeight":"416.52"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ramipril is an ACE inhibitor that prevents the conversion of angiotensin I to angiotensin II, while irbesartan is an angiotensin II receptor blocker (ARB) that directly blocks AT1 receptors. Together, they provide dual inhibition of the renin-angiotensin-aldosterone system (RAAS), resulting in enhanced vasodilation, reduced aldosterone secretion, and greater blood pressure reduction than either agent alone.","oneSentence":"This combination lowers blood pressure by blocking angiotensin II through two complementary pathways: ACE inhibition and angiotensin II receptor antagonism.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:03:46.511Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension in patients not adequately controlled on monotherapy"}]},"trialDetails":[{"nctId":"NCT07262710","phase":"","title":"Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort Study","status":"NOT_YET_RECRUITING","sponsor":"First Teaching Hospital of Tianjin University of Traditional Chinese Medicine","startDate":"2025-12-01","conditions":"Post-stroke Pneumonia","enrollment":13656},{"nctId":"NCT05498675","phase":"","title":"Effect of Sacubitril/Valsartan on Cardiac Function in Hypertensive Patients Stratified by BMI: A Real World Study","status":"RECRUITING","sponsor":"Beijing Friendship Hospital","startDate":"2021-09-01","conditions":"Sacubitril/Valsartan, Hypertension, Obesity","enrollment":180},{"nctId":"NCT00933231","phase":"PHASE3","title":"Comparison of Standard Versus Low Dose Advagraf® With or Without Angiotensin-converting Enzyme Inhibitor (ACEi)/Angiotensin Receptor Blocker (ARB) on Histology and Function of Renal Allografts","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2009-08-17","conditions":"Kidney Transplantation","enrollment":281},{"nctId":"NCT06515678","phase":"","title":"Impact of Antihypertensive Therapy on Recurrence Risk of Ovarian Cancer for Bevacizumab-associated Hypertension","status":"ACTIVE_NOT_RECRUITING","sponsor":"Groupe Hospitalier Pitie-Salpetriere","startDate":"2024-05-20","conditions":"Ovarian Cancer, Antiangiogenic-Associated Hypertension, Adjuvant Bevacizumab","enrollment":9464},{"nctId":"NCT02735707","phase":"PHASE3","title":"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2016-04-11","conditions":"Community-acquired Pneumonia, Influenza, COVID-19","enrollment":20000},{"nctId":"NCT02817360","phase":"PHASE4","title":"NT-proBNP Selected Prevention of Cardiac Events in Diabetic Patients","status":"RECRUITING","sponsor":"Martin Huelsmann","startDate":"2016-02","conditions":"Heart Diseases, Diabetes Mellitus, Type 2","enrollment":2400},{"nctId":"NCT02721342","phase":"","title":"Remission Clinic in Proteinuric Chronic Nephropathies","status":"UNKNOWN","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2009-06","conditions":"Chronic Kidney Disease","enrollment":1500},{"nctId":"NCT04467931","phase":"","title":"ACEI or ARB and COVID-19 Severity and Mortality in US Veterans","status":"COMPLETED","sponsor":"University of Utah","startDate":"2020-01-19","conditions":"Hypertension, COVID","enrollment":22213},{"nctId":"NCT00535925","phase":"PHASE4","title":"Nephropathy In Type 2 Diabetes and Cardio-renal Events","status":"COMPLETED","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2005-10","conditions":"Diabetic Nephropathy","enrollment":850},{"nctId":"NCT04330300","phase":"PHASE4","title":"Coronavirus (COVID-19) ACEi/ARB Investigation","status":"SUSPENDED","sponsor":"National University of Ireland, Galway, Ireland","startDate":"2020-04-30","conditions":"Hypertension, COVID-19","enrollment":2414},{"nctId":"NCT00741585","phase":"PHASE4","title":"Prognostic Value of the Circadian Pattern of Ambulatory Blood Pressure for Multiple Risk Assessment","status":"COMPLETED","sponsor":"University of Vigo","startDate":"2008-09-01","conditions":"Essential Hypertension, Cardiovascular Disease, Stroke","enrollment":21983},{"nctId":"NCT01715584","phase":"PHASE4","title":"Is There an Adverse Drug Reaction Between Renin-Angiotensin System Blockade and Inhaled Anesthetics","status":"UNKNOWN","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2012-07","conditions":"Hypertension","enrollment":80},{"nctId":"NCT00343551","phase":"PHASE3","title":"Efficacy and Safety of Aliskiren 300mg Compared to Irbesartan 300mg and Ramipril 10 mg in the Setting of a Missed Dose for Patients With Essential Hypertension.","status":"COMPLETED","sponsor":"Novartis","startDate":"2006-05","conditions":"Essential Hypertension","enrollment":654},{"nctId":"NCT01500590","phase":"PHASE4","title":"Effect of Renin-angiotensin System Blockers on Glomerular Filtration Rate in Patients With Hypertension, Type 2 Diabetes With Normoalbuminuria","status":"UNKNOWN","sponsor":"Hospital Authority, Hong Kong","startDate":"2011-11","conditions":"Diabetes, Hypertensive Disease","enrollment":1400},{"nctId":"NCT01968759","phase":"PHASE2","title":"Sevelamer in Proteinuric CKD","status":"COMPLETED","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2013-10","conditions":"Chronic Kidney Disease","enrollment":53},{"nctId":"NCT01195818","phase":"NA","title":"Albuminuria Reduction With Renin Angiotensin System Inhibitors in SCA Patients","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2010-09","conditions":"Sickle Cell Disease","enrollment":53},{"nctId":"NCT00095290","phase":"PHASE4","title":"Irbesartan Versus Placebo in Combination With Ramipril for Treatment of Albuminuria","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2004-09","conditions":"Albuminuria","enrollment":400},{"nctId":"NCT00684489","phase":"NA","title":"Renin-Guided Therapeutics in the Management of Untreated, Uncontrolled, or Complicated Hypertension","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2003-09","conditions":"Hypertension","enrollment":52},{"nctId":"NCT00517322","phase":"PHASE4","title":"Left Atrial Remodelling in Hypertension: Effects of Ramipril or Irbesartan","status":"UNKNOWN","sponsor":"Università degli Studi dell'Insubria","startDate":"2007-08","conditions":"Left Atrial Volume, Hypertensive Heart Disease, Antihypertensive Drugs","enrollment":80}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":58,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Avapro"],"phase":"marketed","status":"active","brandName":"Ramipril + Irbesartan","genericName":"Ramipril + Irbesartan","companyName":"Bristol-Myers Squibb","companyId":"bristol-myers-squibb","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination lowers blood pressure by blocking angiotensin II through two complementary pathways: ACE inhibition and angiotensin II receptor antagonism. Used for Hypertension in patients not adequately controlled on monotherapy.","enrichmentLevel":3,"visitCount":2,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}